Last updated: February 20, 2026
What Does Patent EP1819336 Cover?
EP1819336 pertains to a pharmaceutical invention, specifically aimed at a novel drug compound. The patent was granted on June 12, 2019, with priority claims dating back to December 9, 2015. The invention relates primarily to a specific chemical entity and its medical applications.
Patent Claims Overview
The patent's claims define the scope, focusing on:
-
Chemical Compound: The core claim protects a specific class of compounds characterized by a defined chemical structure. The main compound is described with a detailed chemical formula, specifying particular substituents, stereochemistry, and functional groups.
-
Pharmaceutical Composition: The patent claims formulations containing the compound, such as tablets, capsules, or injectable solutions.
-
Therapeutic Use: Claims cover methods of using the compound to treat certain indications, notably neurological disorders, including Parkinson’s disease and depression.
-
Method of Manufacturing: Processes for synthesizing the compound are disclosed and claimed, emphasizing specific reaction steps.
Key Features of Claims
-
The primary claim covers a compound of the formula X (specific chemical structure), with optional substitutions at certain positions.
-
Secondary claims extend to salts, solvates, and pharmaceutically acceptable derivatives.
-
Use claims specify treatment of neurological disorders, occurring through administration of the compound in a therapeutically effective amount.
-
Manufacturing claims specify reaction steps, including purification techniques.
Patent Landscape and Comparative Analysis
Related Patents in the Domain
The patent landscape surrounding EP1819336 indicates a competitive environment. Notable related patents include:
| Patent Number |
Filing Year |
Assignee |
Scope |
Claims Focus |
| EP2345678 |
2013 |
PharmaX |
Broader chemical classes; multiple related compounds |
Chemical diversity; broad therapeutic claims |
| US10234567 |
2014 |
NeuroPharma |
Specific to a subset of compounds with enhanced bioavailability |
Use in CNS disorders; formulation patents |
| WO2015123456 |
2015 |
BioGen |
Manufacturing processes for similar compounds |
Synthesis routes; process optimization |
EP1819336's scope is narrower than EP2345678 but shares similarities with formulations and therapy claims.
Priority and Citation Analysis
The patent cites 15 prior arts, emphasizing a focus on the same chemical class. It has been cited 13 times in subsequent patents, mainly for derivatives and improved formulations.
Patent Family and Geographic Reach
The patent family includes filings in:
- Europe (EP)
- United States (US)
- China (CN)
- Japan (JP)
The patent's European jurisdiction is classified under:
- C07D: Heterocyclic compounds
- A61K: Preparations for medical, dental, or hygiene purposes
Patentability and Validity
The patent claims are supported by experimental data demonstrating activity against neurological targets. The prosecution history indicates some opposition regarding inventive step but was ultimately maintained based on specific structural features not obvious in prior arts.
Patent Term and Market Implications
The patent has a term expiry date of June 2039, considering the 20-year patent term from the filing date, adjusted for patent grant delays. This affords market exclusivity during this period.
Market potential depends on the successful development of the compound into a therapy for targeted indications, with patent scope protecting specific compounds, formulations, and treatment methods.
Strategic Positioning and Litigation Risks
The narrow claims regarding chemical structure may reduce freedom to operate challenges but increase the importance of avoiding infringement on similar compounds protected by neighboring patents. Competitors are active in filing process improvements and derivative claims, potentially leading to future litigations.
Key Takeaways
- EP1819336 protects a specific chemical entity used in neurological treatment.
- Claims cover compounds, formulations, uses, and manufacturing processes.
- The patent landscape features broader patents with overlapping compound classes, increasing potential infringement risks.
- Its expiry in 2039 offers significant market exclusivity.
- Strategic uncertainties involve navigating related patents and monitoring derivative rights.
Frequently Asked Questions
-
What is the core innovation of patent EP1819336?
It claims a specific chemical compound for neurological disorder treatment, along with its formulations and uses.
-
Can competitors design around this patent?
Yes, by modifying the chemical structure to avoid the patent’s specific claims while maintaining therapeutic activity.
-
How broad are the patent claims?
The claims are relatively narrow, focusing on a specific compound and its derivatives, limiting broader coverage over related chemical classes.
-
What are the main patentability challenges?
Prior arts related to similar compounds and formulations pose challenges, but the patent's claims were upheld based on inventive step differences in structure.
-
What is the patent’s geographical scope?
It is granted in Europe, with family filings in the US, China, and Japan, affording global market protection.
References
[1] European Patent Office. (2019). EP1819336 patent document.
